IKT Projected Dividend Yield
Inhibikase Therapeutics Inc ( NASDAQ : IKT )Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. Co. is focused on developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. 20 YEAR PERFORMANCE RESULTS |
IKT Dividend History Detail IKT Dividend News IKT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |